Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial--VIP report no. 1

To determine if photodynamic therapy with verteporfin (Visudyne; CIBA Vision Corp, Duluth, GA) can improve the chance of stabilizing or improving vision (<8 letter loss) safely in patients with subfoveal choroidal neovascularization (CNV) caused by pathologic myopia.


Published in:
Ophthalmology, 108, 5, 841-52
Year:
2001
Publisher:
Elsevier
ISSN:
0161-6420
Keywords:
Laboratories:




 Record created 2011-02-16, last modified 2018-03-08


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)